Curie: Healthcare in Focus

Medicine isn’t always about finding answers—it’s often about navigating the endless gray zones between evidence, patient beliefs, and the realities of daily life. In this episode of Curie, Andrew explores the art of practicing medicine when guidelines meet real-world complexity. From negotiating alternative therapies to facing non-adherence and confronting the limits of influence, this episode draws on real clinician stories to highlight the challenges, frustrations, and moments of humility that define the clinical experience. It’s a conversation for every HCP who’s ever stayed up at night replaying the “unsolvable” cases—and a reminder that progress is some...

In this episode of Curie, host Andrew sits down with Dr. Shikha Jain—GI oncologist, founder of the Women in Medicine nonprofit, and leading voice for gender equity in healthcare. They dive into the most practice-changing GI oncology updates from the latest ASCO meeting, including new evidence on exercise, breakthrough therapies for tough-to-treat cancers, and the promise of innovations like circulating tumor DNA. Beyond the science, Dr. Jain shares her journey as a leader and advocate, how the Women in Medicine Summit has grown into a national force, and why building community and supporting women in medicine is critical to...

In this episode of Curie, Mike investigates how the “Make America Healthy Again” movement is fueling a wellness industry boom—one that blurs the lines between medical innovation, entrepreneurship, and evidence-based care. With physicians and influencers selling peptides, full-body MRIs, and compounded drugs under the guise of personalized medicine, clinicians and experts warn of the growing risks: unproven therapies, regulatory loopholes, and the erosion of public trust. Join us for a deep dive into the forces reshaping prevention, the realities behind the “health freedom” pitch, and what every HCP should watch for in this rapidly evolving landscape.

Are doctors really happy in 2025? Host Andrew uncovers the tough realities behind physician well-being—why burnout is rising, why most doctors would trade pay for time, and what actually makes happiness possible in medicine. Hear candid voices from the front lines and discover why a growing number of doctors are rethinking what matters most.

Join Mike on Curie as we explore the future of medicine in 2050. From AI-driven diagnostics and immersive medical education to precision genomics and telemedicine, this episode uncovers how emerging technologies will reshape healthcare delivery in the U.S. We also discuss ethical challenges and the vital role of physicians in an AI-augmented world. A must-listen for healthcare professionals curious about the next frontier in medicine.

In this investigative episode, Mike explores the complex reasons behind America’s poor health outcomes despite leading the world in healthcare spending. From ultra-processed foods and insulin resistance to chronic inflammation and the promise of new weight-loss drugs, we unravel the biology, environment, and policy factors driving obesity and chronic disease in the U.S. A must-listen for healthcare professionals seeking a deep dive into the nation’s health crisis.

In this investigative episode, Mike dives deep into the unprecedented decision by Health Secretary Robert F. Kennedy Jr. to abruptly fire the entire CDC Advisory Committee on Immunization Practices (ACIP). Exploring the implications for public health, trust in vaccines, and healthcare policy, we examine the controversial backgrounds of new appointees and the urgent reactions from the medical community. What does this political shakeup mean for vaccination rates, patient care, and the future of science-based healthcare in America?

We survey healthcare professionals constantly—on treatments, on tech, on trends. But how often is that research actually used to shape decisions? And what do clinicians really think about being surveyed in the first place?

In this episode, we unpack the role of HCP market research in today’s healthcare economy. Why it’s done, how it’s evolving, and whether it still holds real value. Featuring insights from industry insiders and critical reflections on how pharma and MedTech listen—or don’t—to the voices of frontline care.

In this episode of Curie, we dive into the early but extraordinary results from two CAR-T cell therapy trials that are rewriting what’s possible for glioblastoma—a brain cancer with a devastating prognosis. Andrew takes you through new data from Mass General and the University of Pennsylvania, where some patients have not just responded, but are alive and well nearly two years after treatment.

With quotes from top researchers like Dr. Bryan Choi and Dr. Stephen Bagley, we explore how this groundbreaking treatment works, why a few patients are experiencing durable remissions, and what hurd...

In this extended wrap-up from ASCO 2025, Mike breaks down four defining themes from the meeting: AI’s leap from buzzword to bedside, NIH funding threats that could shake innovation, China’s rising role in global oncology R&D, and five paradigm-shifting clinical trials with the potential to reshape patient care. Featuring insights from ASCO leadership, Google, and frontline HCPs from the ZoomRx panel, this is your all-in-one debrief on the most important takeaways from the year’s biggest oncology conference.

Trump’s drug pricing executive order might sound bold—but what’s behind the rhetoric? In this episode of Curie, host Andrew sits down with Dr. David Introcaso, healthcare policy expert and host of The Healthcare Policy Podcast, to unpack the legal, economic, and political minefield that surrounds America’s $5 trillion healthcare system.

From Medicare price negotiations to pharma's pushback, Dr. Introcaso offers a sharp, no-nonsense take on what’s at stake, what’s realistic, and why this moment might signal a deeper reckoning with how the U.S. approaches cost, coverage, and care.

This is a must-li...

In 2024, over twenty-seven thousand fewer Americans died of a drug overdose—a reversal so steep it stunned even veteran public health researchers. This episode unpacks the factors behind the historic decline: from naloxone’s expanded access to the work of drug-testing labs like UNC’s Opioid Data Lab. We also hear from voices on the front lines, including NPR’s Brian Mann and UNC’s Dr. Nabarun Dasgupta, who remind us that while the tide may be turning, the work is far from over.

Visit curie.md for more curated podcasts, medical news, and games built for healthcare...

GLP-1s like Ozempic and Zepbound transformed obesity and diabetes treatment. But when shortages hit, compounding pharmacies and telehealth startups filled the gap with off-brand versions—cheap, accessible, and often unregulated.

Now, that workaround is over.

In this episode, we examine the FDA’s sweeping May 2025 ban on compounded GLP-1 drugs. What triggered it? What are the safety risks? And why is the industry suddenly pivoting to an older, less effective drug: liraglutide?

With interviews, data, and regulatory context, we break down:

Artificial intelligence is transforming how we detect disease—but what does that mean for the clinician-patient relationship? In this conversation, Dr. Andrew Wilner and Andrew Yukawa explore how diagnostic AI is reshaping everything from radiology to primary care. Together, they unpack the promise, the pitfalls, and the deeply human elements that machines still can’t replicate. From clinical judgment to patient trust, we ask: Where does AI stop, and where must the physician begin?

Artificial intelligence is transforming how we detect disease—but what does that mean for the clinician-patient relationship? In this conversation, Dr. Andrew Wilner and Andrew Yukawa explore how diagnostic AI is reshaping everything from radiology to primary care. Together, they unpack the promise, the pitfalls, and the deeply human elements that machines still can’t replicate. From clinical judgment to patient trust, we ask: Where does AI stop, and where must the physician begin?

In 2025, a six-month-old with a fatal genetic disorder became the first person to receive a CRISPR-based therapy tailored to their unique mutation. In this episode of Curie, host Mike unpacks how a team of researchers and clinicians raced against time to design, test, and deliver a one-time treatment that rewrote the rules of genomic medicine. From the science of base editing to the ethical and logistical hurdles, this is the story of what it took to make personalized gene therapy a reality—and what it means for the future of rare disease care.

A sweeping new executive order from Donald Trump promises to slash prescription drug prices by up to 80%. But behind the bold rhetoric lies a tangle of legal uncertainty, international trade implications, and real clinical consequences. In this episode of Curie, host Mike breaks down what’s actually in the order, why the pharmaceutical industry is pushing back, and what it all means for healthcare professionals. Will your patients benefit—or will this gamble on affordability come at the cost of access?

Ob/Gyns are walking away—and it's not just burnout. In this episode of Curie, we investigate the legal, financial, and political forces driving the crisis in women’s health. What happens when an entire specialty starts to disappear?

From ADHD to borderline personality disorder, mental health content is exploding on TikTok—and teens are listening. But is this wave of awareness helping patients, or muddying the waters for clinicians? In this episode of Curie, we explore how social media is changing the way symptoms are understood, identities are formed, and diagnoses are pursued. Featuring insights from clinicians and research on the rising intersection between mental health and the algorithm.

In this post-conference episode, Mike breaks down five major stories from AACR 2025:

Listen in for a concise roundup of the data and why it matters.

Once considered a short-term fix or semi-retirement gig, locum tenens has become a deliberate career choice for tens of thousands of physicians across the U.S.

We discuss:

Whether you’re considering locum work yourself, or just curious about where physician careers are headed...

A plan to link together massive datasets about autistic Americans has triggered fierce debate. Critics fear it’s a surveillance effort in disguise. Federal agencies say it’s about research. And the autistic community? They're raising serious concerns about privacy, ethics, and unintended consequences. In today’s episode of Curie, Mike unpacks what’s happening inside the Department of Health and Human Services under Secretary Robert F. Kennedy Jr., what’s true, what’s not, and what it could mean for the future of neurodivergent Americans. Love what you hear? Download the Curie app for personalized, in-depth healthcare podcasts curated just...

Seventy years ago, Jonas Salk changed history with the first successful polio vaccine—an innovation that reshaped public health and saved millions of lives. But what does his legacy mean in a world now grappling with vaccine skepticism, science politicization, and resurging preventable diseases? In this episode of Curie, we reflect on Salk’s radical generosity, the ethics of scientific discovery, and what today’s healthcare professionals can still learn from his example.

In today’s Curie Morning Minute, Mike covers top headlines from across the healthcare landscape:

Tune in for your quick daily briefing—under one minute.

In this Curie episode, Matt previews what’s coming at AACR 2025, happening April 25–30 in Chicago. Get ready for a data-packed week with practice-changing trials like KEYNOTE-689 and Beamion LUNG-1, along with fresh momentum in AI-powered oncology, cancer interception, and new modalities like peptide drug conjugates and RNA-targeting agents. From early detection to trial equity, this preview outlines the trends and themes every oncologist should be watching ahead of the meeting.

A cancer vaccine? It’s not science fiction anymore. In this episode of Curie, host Andrew unpacks a groundbreaking personalized vaccine trial led by Dr. Vinod Balachandran at Memorial Sloan Kettering. By training the immune system to recognize mutations unique to each patient’s tumor, this approach is rewriting the rules of cancer care. We explore how mRNA, long known for its role in COVID vaccines, could become the blueprint for a new era in oncology—one that’s personal, programmable, and potentially transformative.

In this special Curie episode, Matt covers the biggest clinical updates from the 2025 American Academy of Neurology Annual Meeting. Learn how CNM-Au8 is showing real signs of remyelination in MS, why AXS-05 may be the next approved treatment for Alzheimer’s agitation, and how Vyepti is delivering long-term migraine relief. We also spotlight Mi-Helper, a noninvasive cooling device for migraines, and the Felix NeuroAI wearable, a smart wristband reducing essential tremor through AI-guided stimulation. Tune in for expert quotes, clinical relevance, and cutting-edge neurology updates.

Measles is back—and it’s not just a public health story, it’s a political one. In this episode of Curie, we explore how the virus is spreading through undervaccinated communities and what the data tells us about the role of vaccine hesitancy. But we also look at what happens when the newly appointed HHS Secretary—Robert F. Kennedy Jr.—has a long record of casting doubt on vaccines. From CDC guideline influence to NIH funding cuts, this episode unpacks how political leadership may be reshaping vaccine confidence in real time.

Is a diagnosis always the right answer? In this episode of Curie, we explore the growing debate around overdiagnosis, featuring neurologist Suzanne O’Sullivan’s provocative insights. As diagnostic rates for autism, ADHD, anxiety, and depression soar, we ask: Are we better at recognizing real struggles—or have we redrawn the line between normal and abnormal? This episode challenges assumptions, shares stories like that of 24-year-old Darcy, and invites healthcare professionals to reconsider the purpose—and the impact—of diagnostic labels.

In this episode, Matt dives into the largest restructuring in the history of the U.S. Department of Health and Human Services. With 10,000 staff laid off across the FDA, CDC, NIH, and beyond, what happens to the public health infrastructure clinicians rely on? Learn what’s changing, who it affects, and what HCPs should be watching closely.

Love what you hear? Download the Curie app from the App Store today.

Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.

Rising drug prices. Critical shortages. Vanishing innovation. In this in-depth episode of Curie, Matt investigates how proposed pharmaceutical tariffs could upend the U.S. healthcare system. With insights drawn from across the supply chain—generic manufacturers, biotech firms, and policy analysts—we explore how a trade policy decision might translate into real-world clinical disruption. If you're wondering how tariffs could affect prescribing decisions, drug a...

Love what you hear? Download the Curie app from the App Store today.

Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.

As political pressures mount, key players in healthcare are shifting away from ‘equity’ toward ‘optimization.’ But what does this really mean for funding, research, and patient outcomes? In this episode of Curie, Matt investigates how Google, insurers, and hospitals are quietly rebranding their healthcare priorities—and why it matters for clinicians.

Love what you hear? Download the Curie app from the App Store today.

Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.

Prior authorizations, endless paperwork, and frustrating denials—healthcare professionals know this battle all too well. But how does this bureaucratic nightmare truly impact patient care? In this episode of Curie, Matt takes you beyond the statistics and into the real-world struggles of physicians navigating the insurance system. You'll hear directly from frontline HCPs who share their experiences with unnecessary delays, overturned denials, and the...

Love what you hear? Download the Curie app from the App Store today.

Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.

Clinica Campesina, a community health center in Colorado, transformed its approach to primary care by using a “pod” system, spatial collocation, and financial incentives to improve efficiency, continuity of care, and patient satisfaction. In this episode, we explore how their unique team-based model improved chronic disease outcomes and streamlined workflows in a high-need patient population.

Love what you hear? Download the Curie app from the App Store today.

Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.

In this episode of Curie, Matt covers three important topics shaping cancer care. A new study confirms that achieving MRD negativity early in AML is critical for long-term survival, reinforcing MRD’s growing role in treatment decisions. We then explore the hard truth about early-phase cancer trials, revealing that only 16.2% of phase 2 treatments ever gain FDA approval—what does this mean for patients enroll...

Love what you hear? Download the Curie app from the App Store for expert-driven healthcare content tailored to your interests.

The National Institutes of Health (NIH) has long been the backbone of U.S. biomedical research—but a new wave of budget cuts could change that. With $4 billion in funding on the line, clinical trials are at risk, research programs are in limbo, and top scientists may start looking elsewhere. In this episode of Curie, Matt investigates how these cuts are already sending shockwaves through the scientific community and what this means for the future of medical in...

Love what you hear? Download the Curie app from the App Store today.

Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.

Dr. Charles Burger transformed his primary care practice in Bangor, Maine, into a high-functioning team model—one that improves efficiency, patient care, and job satisfaction. In this episode, we explore how his practice leverages technology, innovative staff roles, and structured workflows to improve clinical outcomes and patient experience.

Love what you hear? Download the Curie app from the App Store today.

Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.

In this episode of Curie, Matt covers three major developments in oncology. The FDA has approved datopotamab deruxtecan (Datroway) for HR positive, HER2 negative breast cancer, marking a new era for antibody-drug conjugates in this disease. A meta-analysis suggests that the timing of immunotherapy infusions may impact survival outcomes, raising questions about how circadian rhythms influence treatment response. Finally, a global analysis confirms th...

Love what you hear? Download the Curie app from the App Store today.

Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.

Retirement isn’t what it used to be—especially for physicians. With financial pressures, a deep sense of professional identity, and a worsening physician shortage, more doctors are choosing to keep practicing well beyond traditional retirement age. In this episode of Curie, Matt investigates why some physicians never step away, the rise of encore careers, and what this means for the future of medici...

Love what you hear? Download the Curie app from the App Store today.

Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.

In this episode of Curie, Matt breaks down three major updates in oncology. ASCO has released updated guidelines for advanced ovarian cancer, emphasizing primary cytoreductive surgery over neoadjuvant chemotherapy when feasible. The Mammo-50 trial challenges the standard of annual mammographic surveillance for breast cancer survivors over 50, showing that less frequent screening is non-inferior. Finally, the eNRGy trial confirms the efficacy of zenocutuzumab in tr...